SPY314.84-2.75 -0.87%
DIA261.04+0.22 0.08%
IXIC10,390.84-226.60 -2.13%

INOVIO Says '94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 after two doses of INO-4800 in trial with 40 healthy volunteers in preliminary analyses'

Benzinga · -